Immuron Limited American Depositary Shares - IMRN STOCK NEWS

Immuron (ASX: IMC; NASDAQ: IMRN) has filed a pre-IND application with the FDA for IMM-529, aimed at treating recurrent Clostridioides difficile infections (CDI). CDI affects over 400,000 people annually in the U.S., causing over 30,000 deaths. IMM-529 is being developed as an adjunct therapy to standard antibiotics, targeting Toxin B, spores, and vegetative cells of C. diff. Pre-clinical studies have shown promising results, including 80% prevention of primary disease and 67% protection against recurrence. The projected base case yearly revenue for IMM-529 is US$93 million, with potential expansion to US$141 million if used for first recurrence patients. The drug's oral dosing is considered advantageous over current complex treatments. Immuron is working with Monash University to produce antibodies from bovine colostrum. The PR highlights the urgent need for new CDI treatments due to rising antibiotic resistance.

Immuron's CEO, Steven Lydeamore, will present at the Emerging Growth Conference on June 13, 2024. Immuron, an Australian biopharmaceutical company traded on ASX (IMC) and NASDAQ (IMRN), invites individual and institutional investors, as well as advisors and analysts, to join the interactive presentation. The session starts at 2:00 PM US Eastern Standard Time and will last for 12 minutes. Participants are encouraged to submit questions in advance or during the event. If unable to attend live, an archived webcast will be available on EmergingGrowth.com and its YouTube channel.

Immuron (IMRN), an Australian biopharmaceutical company, announced significant board changes on May 31, 2024. Dr. Roger Aston resigned as Non-Executive Director after serving since 2012, including as Chairman until 2023. Over his tenure, Immuron advanced its commercial and clinical programs, especially in diarrhoea prevention and gut health, strengthened by its partnership with the US Military. Dr. Aston's leadership was pivotal during capital raisings and the COVID-19 pandemic. Effective June 1, 2024, Dr. Jeannie Joughin, with extensive experience in immunology and senior roles at major pharmaceutical companies, will join as a Non-Executive Director, expected to enhance Immuron's strategic and commercial direction.

Immuron CEO Steven Lydeamore will be presenting at Peak Asset Management's Peak Sky High luncheon in Melbourne on June 1, 2024.

Immuron , an Australian-based biopharmaceutical company, is listed on the ASX as IMC and NASDAQ as IMRN.

The presentation slide deck is available on the company's website.

This press release was authorized by the directors of Immuron.

Immuron , an Australian biopharmaceutical company, will be presenting at the Emerging Growth Conference on May 8, 2024. Investors, analysts, and advisors can interact with the CEO, Steven Lydeamore, during the live event. Questions can be submitted in advance or during the presentation.

Immuron announces the resignation of Non-Executive Director Stephen Anastasiou to focus on other business interests. Stephen has been with the company since 2013, contributing to the launch of Travelan® in the USA and Canadian markets and dual listing on NASDAQ (IMRN). His departure is aimed at restructuring his business commitments to spend more time with family and pursue personal interests. Immuron Chairman expresses gratitude for Stephen's marketing and clinical contributions and wishes him success in future endeavors.

Immuron (ASX: IMC; NASDAQ: IMRN) announces a Live Virtual Event featuring positive Phase 2 Travelan results and upcoming Phase 3 clinical trials. The event will showcase the company's success in developing oral immunotherapeutics for gut-mediated diseases, with significant reductions in diarrhea cases and promising revenue projections.

Immuron (IMRN) reports significant sales growth for Travelan®, an immune supplement, in Australia and the USA. FYTD Mar 2024 sales reached AUD$3.6 million, up 154% from the prior year, with Australia leading at AUD$2.8 million, up 234%. Sales on Walmart.com have commenced. The company aims to expand brand awareness and distribution in North America.

Immuron Limited announces positive interim topline results for Travelan® in preventing moderate to severe diarrhea caused by ETEC. The Phase 2 study showed significant protective efficacy with a single daily dose, supported by funding from the U.S. Department of Defense. The study demonstrated a 36.4% protective efficacy against moderate to severe diarrhea and a 66.7% protective efficacy against severe diarrhea compared to the placebo group. Additionally, there was an 83.3% reduction in subjects needing early antibiotic treatment and a 100% reduction in subjects requiring IV fluids post challenge in the Travelan® group. The study also reported a 55.6% reduction in adverse events associated with the ETEC challenge in the Travelan® group. The Phase 2 study data supported the excellent safety and tolerability profile of Travelan®.